**Supplemental Table 2. SBP of LCZ696 and ARB**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study** | **LCZ696** | **LCZ696** | **ARB** | **ARB** |
| **baseline** | **final** | **baseline** | **final** |
| **Ruilope LM [6]****(NCT00549770)** | 100 mg200 mg400 mg | 154.9±11.9156.8±12.0156.3±12.3 | 130.0±10.5128.1±10.9126.0±11.1 | Valsartan 80mgValsartan 160mgValsartan 320mg | 154.8±10.5155.3±10.8156.0±11.5 | 134.0±11.0131.9±11.5131.8±12.1 |
| **Kario K [7]****(NCT01193101)** | 100 mg200 mg400 mg | 155.7±10.7155.7±9.2153.9±9.4 | 127.1±10.1128.0±8.5123.5±10.0 | — | — | — |
| **RATIO [8]****(NCT01281306)** | 400 mg | 159.6±7.0 | 126.8±8.1 | Valsartan 320mg | 160.0±7.3 | 133.9±8.8 |
| **Supasyndh O [9]****(NCT01615198)** | 100mg200mg | 160.5±8.4160.5±8.4 | 126.0±9.0130.9±9.5 | Olmesartan 10mgOlmesartan 20mg | 160.0±8.0160.0±8.0 | 130.9±8.1140.3±9.0 |
| **PARAMETER [10]****(NCT01692301)** | 200 mg | 158.4±13.4 | 127.0±10.1 | Olmesartan 20mg | 158.8±13.5 | 134.3±11.1 |
| **Schmieder RE [14]****(NCT01870739)** | 400 mg | 155.3±9.0 | 129.4±11.3 | Olmesartan 20mg | 155.0±9.1 | 134.0±12.8 |
| **Wang TD [16]****(NCT01681576)** | 400 mg | 147.0±9.7 | 124.0±10.1 | Valsartan 320mg | 147.5±12.1 | 130.8±11.1 |
| **NCT01599104 [11]** | 200 mg400 mg | — | — | Olmesartan 20 mg | — | — |
| **NCT01785472 [12]** | 200 mg400 mg | — | — | Olmesartan 20mg | — | — |
| **NCT01876368 [13]** | 200 mg | — | — | Olmesartan 20mg | — | — |
| **NCT01353508 [15]** | 400 mg  | — | — | Valsartan 160mg | — | — |
| **NCT01256411 [17]** | 200 mg400 mg | — | — |  — | — | — |

* **: no report; ARB: angiotensin receptor blockers**